Articles tagged with B Cell Lymphoma
Researchers have discovered a CD19-dependent pathway that contributes to the growth of B cell lymphomas. High levels of CD19 correlate with increased MYC activity, suggesting a new target for therapies currently in clinical trials.
Researchers have discovered the FBXO11 gene as a novel tumor suppressor in B-cells, which regulates BCL6 protein levels. Deletions or mutations of FBXO11 contribute to DLBCL's development, with reconstitution of its expression inhibiting proliferation and inducing cell death.
A new study reveals that more intensive chemotherapy regimens significantly improve event-free survival and reduce mortality in younger patients with aggressive diffuse large B-cell lymphoma. Younger patients who received dose-intensive chemotherapy had an 81% event-free survival rate, compared to 67% for those on standard treatment.
Researchers at the University of Maryland School of Medicine have found a complex molecular relationship between ERK and CHK2 proteins, which could lead to new treatments for diffuse large B-cell lymphoma. The study showed that inhibiting both proteins simultaneously killed more cancer cells than treating them separately.
A modified chemotherapy regimen combining reduced CHOP doses with rituximab has shown substantial response and improved survival in very elderly patients with diffuse large B-cell lymphoma. The R-miniCHOP regimen is well-tolerated, with a high overall response rate and low treatment toxicity.
Researchers at Weill Cornell Medical College have identified a potential new combinatorial therapy for diffuse large B cell lymphoma, the most common form of non-Hodgkin lymphoma. Combining an inhibitor of BCL6 with either HDAC proteins or Hsp90 protein enhanced killing of cancer cells in vitro and suppressed tumor growth in mice.
A phase III study will evaluate Revlimid as a maintenance therapy for elderly patients with diffuse large B-cell lymphoma. The study aims to determine progression-free survival and overall survival associated with Revlimid compared to placebo.
Researchers at the University of Texas M. D. Anderson Cancer Center have developed a new three-drug combination therapy that spares patients from prolonged myelosuppression, a potentially lethal side effect of traditional treatments. The treatment achieved a remission rate of 96% in patients with indolent B cell lymphoma.
Researchers used FLT PET to monitor treatment response in DLBCL patients treated with R-CHOP chemotherapy. Treatment led to temporary increases in FLT uptake, indicating increased DNA synthesis and tumor cell proliferation. This suggests that FLT PET may be a sensitive tool for differentiating non-responding tumors.
Researchers found that mir-17-92 cluster microRNAs are overexpressed in most common cancers, including B-cell lymphoma and colorectal carcinomas. This overexpression may contribute to cancer development and progression.
Researchers have identified a set of six genes that correlate with survival in diffuse large B-cell lymphoma, including LMO2, BCL6, and CCND2. The findings suggest that molecular profiling may help refine prognoses for this difficult-to-treat blood cancer.
The study found that adding rituximab to the CHOP regimen as a first-line treatment did not significantly impact overall response rates or early disease progression. Maintenance rituximab showed promise in prolonging time-to-treatment failure, but had no effect on overall survival.
Researchers create animal model that develops three types of lymphoma, shedding light on genetic mutations and cell signal pathways. The discovery holds promise for developing new treatments to block cancer-causing signals.